Zenas BioPharma (ZBIO) Profit After Tax (2023 - 2026)

Zenas BioPharma's Profit After Tax history runs 4 years deep, the most recent figure standing at -$81.0 million for Q1 2026.

• In Q1 2026, Profit After Tax fell 141.23% year-over-year to -$81.0 million; the TTM figure through Mar 2026 stood at -$425.1 million (down 161.25% YoY), while the FY2025 annual figure was -$377.7 million, down 140.62% from the prior year.
• Profit After Tax was -$81.0 million for Q1 2026 at Zenas BioPharma, up from -$240.4 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $35.6 million in Q3 2023 to a low of -$240.4 million in Q4 2025.
• Historically, Profit After Tax has averaged -$55.0 million across 4 years, with a median of -$38.6 million in 2024.
• Biggest YoY gain for Profit After Tax was 20.77% in 2025; the steepest drop was 357.21% in 2025.
• A 4-year view of Profit After Tax shows it stood at -$24.6 million in 2023, then sank by 113.77% to -$52.6 million in 2024, then plunged by 357.21% to -$240.4 million in 2025, then surged by 66.32% to -$81.0 million in 2026.
• The last three Profit After Tax figures came in at -$81.0 million (Q1 2026), -$240.4 million (Q4 2025), and -$51.5 million (Q3 2025), per Business Quant data.